Cellect(QNRX)2023-03-09 19:27Financial Data and Key Metrics Changes - As of December 31, 2022, cash and marketable securities were 15.2 million as of September 30, 2022 [25] - The company reported a net loss of 9.4 million for the full year [26] Business Line Data and Key Metrics Changes - Research and development expenses were 2.7 million for the year, primarily related to Netherton Syndrome clinical trials [26] - General and administrative expenses were 6.6 million for the year [26] Market Data and Key Metrics Changes - The company established 8 commercial partnerships covering 60 countries, indicating a broad market reach for its products [4] Company Strategy and Development Direction - Quoin intends to self-commercialize QRX003 and other pipeline products in the U.S. and Europe, aiming for a global launch [4] - The company is exploring M&A opportunities in the rare and orphan disease space, focusing on acquiring derisked late-stage assets [19][46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong cash position, which extends the financial runway into the second half of 2024, allowing for continued clinical development and potential M&A activities [19] - The company is optimistic about the progress of its clinical trials and anticipates presenting data in 2023 [27] Other Important Information - The company is working with regulatory consultants to explore conditional marketing approval for QRX003 in Europe, which could expedite commercialization [22] - Engagement with the Netherton community has been emphasized as critical for building awareness and support for the company's clinical programs [49] Q&A Session Summary Question: Expectations for patient recruitment in Phase III trial - Management indicated that recruitment is proceeding as expected and clinical data is anticipated to be available this year [29][30] Question: Percentage of severe Netherton Syndrome patients treated with off-label biologics - Management estimated that approximately 15% to 20% of severe Netherton patients are currently treated with off-label biologics, which are not reimbursed for this indication [35] Question: Breakdown of SG&A expenses - Management clarified that SG&A expenses appear high relative to R&D due to the timing of clinical studies and the compact nature of current trials [38][40]